Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Solid Biosciences Q4 2023 Net Loss Of $(20.3)M Compared To $(15.2)M YoY, With Cash Balance Of $123.6M Which Is Expected To Provide Cash Runway Into 2026

Author: Benzinga Newsdesk | March 13, 2024 07:49am

Posted In: SLDB